Form PTO-1449
INFORMATION DISCLOSURE CITATION
INFORMATION DISCLOSURE CITATION IN AN APPLICATION

TRADEMARY

(Use several sheets if necessary)

Docket Number 421842000400	Application Number 10/627,372				
Applicant					
Harriha	r A. PERSHADSINGH				
Filing Date July 24, 2003	Group Art Unit Not Yet Assigned				
Mailing Date November 21, 2003					

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
180	l.	02/15/2000	RE 36,575	Meguro et al.			
	2.	07/07/1992	5,128,356	Naka et al.			
	3.	11/10/1992	5,162,326	Naka et al.		· ·	
	4.	03/23/1993	5,196,444	Naka et al.			
	.5.	09/07/1993	5,243,054	Naka et al.			
·	6.	10/05/1993	5,250,554	Naka et al.			
	7.	02/08/1994	5,284,661	Morimoto et al.			
	8.	07/12/1994	5,328,919	Naka et al.			
	9.	10/11/1994	5,354,766	Naka et al.			<del></del>
	10.	02/14/1995	5,389,641	Naka et al.			·
	11.	03/28/1995	5,401,764	Naka et al.			
	12.	10/31/1995	5,463,073	Takehiko et al.			· · · · · · · · · · · · · · · · · · ·
	13.	03/05/1996	5,496,835	Kubo et al.			
	14.	03/19/1996	5,500,427	Kubo et al.			
	15.	04/09/1996	5,506,245	Regnier et al.	•		
	16.	07/30/1996	5,541,229	Narr et al.			
	17.	10/15/1996	5,565,469	Mihm et al.			
	18.	12/10/1996	5,583,141	Naka et al.			
	19.	12/24/1996	5,587,393	Narr et al.			
	20.	01/07/1997	5,591,762	Hauel et al.		· <del>-</del>	
	21.	01/14/1997	5,594,003	Hauel et al.			
	22.	02/11/1997	5,602,127	Hauel et al.			
	23.	03/25/1997	5,614,519	Hauel et al.			
	24.	06/17/1997 .	5,639,773	Kubo et al.			
	25.	09/02/1997	5,663,186	Nelson et al.			
ci	26.	09/02/1997	5,663,187	Nelson et al.			
lle	27.	11/04/1997	5,684,029	Narr et al.			

	EXAMINER: 6 - Weekto	DATE CONSIDERED:	1-25-08
--	----------------------	------------------	---------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Application Number 10/627,372 Form PTO-1449 Docket Number 421842000400 INFORMATION DISCLOSURE CITATION **Applicant** Harrihar A. PERSHADSINGH IN AN APPLICATION NOV 2 4 2000 (Use several sheets if necessary) Filing Date July 24, 2003 Group Art Unit Not Yet Assigned Mailing Date November 21, 2003 BADRIARKO 12/02/1997 28. 5,693,651 Nomura et al. 12/30/1997 Naka et al. 29. 5,703,110 01/06/1998 30. 5,705,517 Naka et al. 04/07/1998 31. 5,736,555 Naka et al. 5,741,803 32. 04/21/1998 Pool et al. Lohray et al. 33. 09/01/1998 5,801,173 09/22/1998 Ogawa et al. 5,811,439 34. 35. 10/06/1998 5,817,075 Giungo 10/20/1998 5,824,694 Kurtz et al. 36. 37. 10/27/1998 5,827,865 Haigh et al. 38. 11/10/1998 5,834,501 Fujita et al. 39. 12/01/1998 | 5,843,172 Yan 12/01/1998 Pershadsingh et al. 40. 5,843,970 12/08/1998 Doebber et al. 41. 5,847,008 01/12/1999 42. 5,859,051 Adams et al. 01/26/1999 Narr et al. 5,864,043 43. 02/09/1999 Giungo et al. 44. 5,868,728 02/09/1999 5,869,495 45. Haigh et al. 03/16/1999 Naka et al. 5,883,111 46. 03/23/1999 47. 5,885,997 Lohray et al. 48. 03/23/1999 5,886,014 Fujita et al. 03/30/1999 49. 5,889,025 Lohray et al. 03/30/1999 5,889,032 Lohray et al. **50.** Kliewer et al. 05/11/1999 5,902,726 51. 06/08/1999 Pool et al. 5,910,592 **52.** 07/06/1999 5,919,782 Lohray et al. 53. 07/20/1999 5,925,656 54. Kallam et al. 08/03/1999 Sohda et al. 55. 5,932,601 08/17/1999 5,939,442 Evans et al. 56. 5,952,356 57. 09/14/1999 Ikeda et al. Re DATE CONSIDERED: 1.52-02 **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

orm PTC	)-1449		•		Docket Number 421842000400	Α	pplication N	lumber 10/627,372
THEOL			SURE CITATION	[	Applicant	ar A. PERSI		
188	Let'	AN APPLIC			<del></del>			<del></del>
2 4 2003	(U	se several sheets if	necessary)		Filing Date July 24, 2003		roup Art Un	nit Not Yet Assigned
	Ų.				Mailing Date November 21, 2003	<del></del>		
RADEMAN	8)	00/14/1000	5.050.500	<u> </u>				<del></del>
(A)	58.	09/14/1999	5,952,509	· ·	et al.			
	59.	09/28/1999	5,958,942		tani et al.			
	60.	09/28/1999	5,958,961		et al.			
	61.	10/05/1999	· · · ·		et al.		<del></del>	
	62.	10/05/1999	5,962,491		et al.			
	63.	10/12/1999	5,965,584	Ikeda	et al.			<del> </del>
	64.	10/19/1999	5,968,589		kami		·	
	65.	10/26/1999	5,972,959	Yana	gisawa et al.			
	66.	10/26/1999	5,972,970		a et al.			
	67.	11/02/1999	5,977,365	Fujit	a et al.			
	68.	11/16/1999	5,985,884	Lohr	ay et al.			
	69.	11/23/1999	5,990,139	Yano	et al.			
	70.	12/21/1999	6,004,989	Naka	et al.			
	71.	12/28/1999	6,008,237	Saho	o et al.			
	72.	01/04/2000	6,011,031	Lohr	ay et al.			
	73.	01/04/2000	6,011,036	Lohr	ay et al.			
	74.	02/01/2000	6,020,382	Doeb	ber et al.			
	75.	02/08/2000	6,022,897	Evan	s et al.			
	76.	02/22/2000	6,028,088	Persl	nadsingh et al.			
	77.	07/11/2000	6,087,384	Mats	ui et al.			
	78.	07/11/2000	6,087,385	Persh	nadsingh et al.			
	79.	07/18/2000	6,090,836	Adar	ns et al.			
	80.	07/18/2000	6,090,839	Adar	ns et al.		•	
	81.	08/08/2000	6,100,252	Naka	et al.			
	82.	08/08/2000	6,100,403	Saito	et al.		<del></del>	
	83.	08/15/2000	6,103,742	Ikeda	et al.			
	84.	09/05/2000	6,113,907	Khw	aja et al.			
	. 85.	09/12/2000	6,117,893		a et al.			
	86.	11/21/2000	6,150,371	·	vara et al.			
The	87.	12/12/2000	6,160,000	<del></del>	ns et al.			
EXAMI	NER:	40.4	led the		DATE CONSIDERE	D:		

Form PTO-1449			Docket Number 421842000400 Application Number 10/627,372						
AND ATION DISCLOSURE CITATION				Applicant					
IN AN APPLICATION				Harrihar A. PERSHADSINGH					
NOV 242		se several sheets if i	necessary)		Filing Date July 24, 2003		Group Art Unit N	lot Yet Assig	med
P.		•		`	Mailing Date November 21, 20	003			•
RADRAN	AKON								
	88.	03/13/2001	6,200,995	De L	a Brouse-Elwood et al.				
	89.	05/08/2001	6,228,874	Inada	et al.				
	90.	05/15/2001	6,232,334	Naka	et al.				
	91.	12/11/2001	6,329,415	Cirill	o et al.				
	92.	12/25/2001	6,333,325	Cirill	o et'al.				
	93.	02/19/2002	6,348,481	Inada	et al.				·-
	94.	03/05/2002	6,353,011	Persh	nadsingh				
	95.	03/12/2002	6,355,808	Naka	et al.				<u> </u>
	96.	03/19/2002	6,358,945	Breit	felder et al.		_		
	97.	04/09/2002	6,369,098	Persh	nadsingh				
	98.	04/16/2002	6,372,773	Rega	n				
	99.	07/02/2002	6,414,002	Chen	g et al.				
	100.	07/02/2002	6,414,008	Hauel et al.					•
	101.	07/16/2002	6,420,405	Inada et al.					
	102.	08/13/2002	6,432,993	Fujita	a et al.				
	103.	08/13/2002	6,432,996	Tamu	ura et al.			•	
	104.	09/17/2002	6,451,832	Ries	et al.				
	105.	10/22/2002	6,468,996	Jeppe	esen et al.				
	106.	10/22/2002	6,469,039	Haue	el et al.				•
	107.	11/05/2002	6,476,023	Cirill	lo et al.				
	108.	11/12/2002	6,479,524	Priep	ke et al.				
lu	109.	11/26/2002	6,486,188	Pede	rsen et al.		*		
	Ref. No.	Date	Document No.		Country	Class	Subclass	Trans! YES	lation NO
1017	110.	07/17/1997	WO 97/25042	WIP	0				
11.	111.	08/07/1997	WO 97/28137	WIP	0				
1	112.	02/12/1998	WO 98/05331	WIP	0 .				
19	113.	12/23/1998	WO 98/57941 .	WIP	0				
13	-114.	12/09/1999	WO 99/62870	WIP	0				
EXAMIN	IER:	e cete			DATE CONSIDER	RED:			
		al if citation cons	idered, whether or not the		on conforms with MPEP 609.  next communication to application		ne through the c	itation if no	ot in

Form PTO-1449			Docket Number 421842000400 Application Number 10/627,3		umber 10/627,372			
PATEUR MATION DISCLOSURE CITATION			Applicant					
Pr. Q	£ 1/2	N	AN APPLIC	ATION		Harrihar A	A. PERSHADSINGH	
		E VUS	e several sheets if i	necessary)		Filing Date July 24, 2003	Group Art Uni	it Not Yet Assigned
71-7	2 4 20					Mailing Date November 21, 2003		
	A					<u>L </u>		
RA	DELIN	115.	12/09/1999	WO 99/62871	WIP	0		
U	11	116.	12/09/1999	WO 99/62872	WIP	0		
,	7	117.	07/27/2000	WO 00/27832	WIP	0 .		
	ノ	118.	01/04/2001	WO 01/00603	WIP	0		
,	-	119.	02/22/2001	WO 01/12612 ·	WIP	O ·		
	7	120.	03/29/2001	WO 01/21602	WIP	0		
	/	121.	05/17/2001	WO 01/34094	WIP	0		
The		122.	10/03/2002	WO 02/076177	WIP	0		
-6.00	1				•			
,		Ref.	Title		<del></del>			
		No.				•		
10		123.				ning and Expression of Full-		
	· -		i e	•	Janua	ry 14, 1995, located at <a href="http://example.com/ry-14">http://example.com/ry-14</a> , located at <a 12,="" 199<br="" created="" href="http://example.com/&lt;/td&gt;&lt;td&gt;://www.ncbi.nlr&lt;/td&gt;&lt;td&gt;n.nih.gov&gt; last&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;124&lt;/td&gt;&lt;td&gt;&lt;del&gt;&lt;/del&gt;&lt;/td&gt;&lt;td&gt;ptember 24, 2003.&lt;/td&gt;&lt;td&gt;2 11-70&lt;/td&gt;&lt;td&gt;NA Clarina Chromosomol&lt;/td&gt;&lt;td&gt;Manning and E&lt;/td&gt;&lt;td&gt;unational&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;1&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;124.&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;NA Cloning, Chromosomal I ome Proliferator Activated R&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;_&lt;/td&gt;&lt;td&gt;•&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;ov&gt; last visited on September&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;125.&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;lation and Characterization of&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;Receptor: A&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;nily" june="" on="">sited on September 24, 2003</a>		
		126.	<del></del>			e Development of Sequence-		r Human
	<u>-</u>	120.				, 1993, located at <a 2003<="" 24,="" created="" href="http://www.new.new.new.new.new.new.new.new.new.&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;on Septembe&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;· · · · · · · · · · · · · · · · · · ·&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;127.&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;entification of Nuclear Recep&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;•=-&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;_&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;_&lt;/td&gt;&lt;td&gt;ger Motif Sequences" isited="" on="" september="" td=""><td></td><td>1993, located at</td></a>		1993, located at
		128.	<u> </u>	<del></del>		man and Rat TR4 Orphan R		y a Subclass of the
		120.				l on September 15, 1994, loc		
			<a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last visited on September 24, 2003.					
}		129.				New Orphan Member of the		ne Receptor
	1		Superfamily Closely Related to Rev-Erb" created on May 8, 1995, located at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last visited on September 24, 2003.					
		130.	<del></del>					r Activated
IA	Receptor Gamma cDNA: Expression in Hematopoietic Cells and Chromosomal Mapping" create				Sapping" created on			
December 26, 2001, located at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last visited on September 24, 200					tember 24, 2003.			
EX	AMI	NER:	14			DATE CONSIDERED:	1-28-	05
4						on conforms with MPEP 609. Dra	w a line through th	e citation if not in
Con	conformance and not considered. Include a copy of this form with next communication to applicant.							

Form PTO-1449			Docket Number 421842000400	Application Number 10/627,372		
EVEGR	TAM	ON DISCLOSURE CITATION	Applicant			
C the	W	AN APPLICATION	Harrihar A. PEI	RSHADSINGH		
NDV 2421		se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned		
B RDI E 7 A	W 33		Mailing Date November 21, 2003			
	, TOP					
MADERIT	131.	GenBank Accession No. M24748, "Ch	aracterization of a Third Human	Thyroid Hormone Receptor		
1GC+		Coexpressed with Other Thyroid Horm located at <a href="http://www.ncbi.nlm.nih.go">http://www.ncbi.nlm.nih.go</a>				
	132.	GenBank Accession No. M24857, "A on November 8, 1994, located at <a href="https://www.november.new.november.20">https://www.november.20</a>				
_	133.	GenBank Accession No. M24898, "Tw Binding Capacities are Transcribed fro on November 7, 1994, located at <a created<="" href="https://www.new.november.new.new.new.new.new.new.new.new.new.new&lt;/td&gt;&lt;td&gt;m Opposite DNA Strands of the&lt;/td&gt;&lt;td&gt;Same Genetic Locus" td=""></a>				
	134.	GenBank Accession No. M26747, "Hu Members of a New Superfamily of Enl- <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last vis	nancer Binding Proteins" created	<del>-</del>		
	135.	GenBank Accession No. M29960, "Mo Steroid Receptor with Multiple Ligand <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last vis	-Binding Domains" created on A	_		
	136.	GenBank Accession No. M64497, "Re Member of the Steroid Receptor Super <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last vis	family" created on January 31, 1	<u> </u>		
	137.	GenBank Accession No. M81385, "Ex- Homologue-1 as a Potential Steroidoge <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last vis	enic Factor in Rat Ovary" created	<u>-</u>		
	138.	GenBank Accession No. M84820, "Purwith which RAR or TR Heterodimerize 1995, located at <a href="http://www.ncbi.nlm">http://www.ncbi.nlm</a>	es to Bind Target Sequences Eff	iciently" created on January 9,		
	139.	GenBank Accession No. S65876, "Cha Key Regulator of Steroid Hydroxylase <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> > last vis	Gene Expression" created on M	•		
_	140.	GenBank Accession No. S77482, "The Mouse Homolog of the Orphan Nuclear Receptor Tailless is Expressed in the Developing Forebrain" created on September 27, 1995, located at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last visited on September 24, 2003.				
	141.	GenBank Accession No. U10375, "Differential Expression and Activation of a Family of Murine Peroxisome Proliferator-Activated Receptors" created on July 22, 1994, located at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last visited on September 24, 2003.				
	142.	GenBank Accession No. U11551, "A Novel Bacillus Associated with Diseased Fish" created on July 19, 1994, located at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last visited on September 24, 2003.				
lle-	143.					
EXAMIN	JER:	lo, celeb	DATE CONSIDERED:	[-21-05		
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.					

Form	PTO	-1449		Docket Number 421842000400	Application Number 10/627,372				
AN	FOR	MATI	ON DISCLOSURE CITATION	Applicant .					
10	\$ PC .	Will	AN APPLICATION	Harrihar A. PERSHADSINGH					
ANTON	a / an	- Enus	se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned				
NOV 2 多	L 4 W	m æi		Mailing Date November 21, 2003					
		10%							
W.	DEMA	144.	GenBank Accession No. U14534, "Ub Activation by Retinoic Acid and Thyro <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> > last vis	oid Hormone Receptors" created	•				
$\bigcap$	<i>-</i>	145.	GenBank Accession No. U14666, "Clo Germ Cell Development" created on M visited on September 24, 2003.	ning of a Novel Orphan Receptor	•				
	-	146.	GenBank Accession No. U16997, "RO Subfamily that is Highly Expressed in <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last vis	Skeletal Muscle" created on Apr	_				
	1	147.	GenBank Accession No. U18374, "Ide: Metabolites" created on June 21, 1995, September 24, 2003.						
		148.	GenBank Accession No. U38480, "Character of Particle of September 24, 2003."						
		149.	GenBank Accession No. X06614, "A 7 Hormone Receptor, in the v-erbA Once September 12, 1993, located at <a href="http://">http://</a>	ogene Product and in the Retinoi	c Acid Receptor" created on				
	۵۰ .	150.	GenBank Accession No. X12794, "Ide Molecular Cloning: The Gene Products 25, 1997, located at <a href="http://www.ncbi.ide">http://www.ncbi.ide</a>	s of the Two are Highly Related	to Each Other" created on June				
	-	151.	GenBank Accession No. X12795, "Ide Molecular Cloning: The Gene Products 25, 1997, located at <a href="http://www.ncbi.ide">http://www.ncbi.ide</a>	s of the Two are Highly Related	to Each Other" created on June				
	-	152.	GenBank Accession No. X51416, "Ideacreated on April 3, 1997, located at <a href="https://doi.org/10.2003/10.2003">https://doi.org/10.2003/10.2</a>						
		153.							
	-	154.							
GenBank Accession No. X75163, "A Novel Nuclear Receptor Superfamily Member in Xenopus Associates with RXR, and Shares Extensive Sequence Similarity to the Mammalian Vitamin D3 Receptor" created on February 2, 1994, located at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last visited on September 24, 2003.									
EXA	AMIN	IER: \	10 · 10 ·	DATE CONSIDERED:	}				
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.								

Form PTO-1449				Docket Number 421842000400	Application Number 10/627,372			
INFORMATION DISCLOSURE CITATION		ON DISCLOSURE CITATION	Applicant					
IN AN APPLICATION			AN APPLICATION	Harrihar A. PE	RSHADSINGH			
NETT	2 4 20	m E Us	se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned			
				Mailing Date November 21, 2003				
	PASSAGE	K. Colfrid						
	( المراد الم	156.	GenBank Accession No. X75918, "NO to the Steroid/Thyroid Hormone Recep <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last vis	otor NAK1/TR3" created on Janu	_			
	ン	157.	GenBank Accession No. X76930, "Clo Hepatocyte Nuclear Factor 4 Indicate t November 8, 1994, located at <a created="" href="http://w&lt;/td&gt;&lt;td&gt;he Presence of Two Isoforms in&lt;/td&gt;&lt;td&gt;Human Liver" on<="" td=""></a>					
	1	158.	GenBank Accession No. Y00291, "A Nappropriately Expressed in Human Hat <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last	Iepatocellular Carcinoma" create	ed on January 14, 1991, located			
		159.	GenBank Accession No. Z49826, "Hur Distinct and Differentially Expressed C <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> last vis	Genes" created on September 6,				
	<b>ئے</b>	160.	Adams, A.D. et al. (2003). "Amphipath Agonists," Bioorganic & Medicinal Ch		zoles; Human PPaR γ, δ and α			
	-	161.	Alberti, K.G.M.M. and Zimmet, P.Z. (1998). "Definition, Diagonisis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation," <i>Diabet. Med.</i> 15:539-553.					
	4 -	162.	Almansa, C. et al. (1996). "Diphenylp: Antagonists," J. Med. Chem. 39:2197-2		ective Angiotensin II			
		163.	Almansa, C. et al. (1997). "Synthesis a AT <sub>1</sub> Selective Angiotensin II Receptor Chem. 40:547-558.	•	•			
		164.	American Diabetes Association (2002) 25(4):742-749.	. "The Prevention or Delay of T	ype 2 Diabetes," Diabetes Care			
		165.	American Medical Association. (2001) Cholesterol Education Program (NCEI High Blood Cholesterol in Adults (Adu	P) Expert Panel on Detection, Ev	aluation, and Treatment of			
		166.	American Medical Association. (2002). "Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),"  JAMA 288(23):2981-2997.					
***	167. Ashton, W.T. et al. (1994). "Triazolinone Biphenylsulfonamide Derivatives as Orally Active Angiotensin II Antagonists with Potent AT <sub>1</sub> Receptor Affinity and Enhanced AT <sub>2</sub> Affinity," J. Med. Chem. 37:2808-2824.							
71	168. Atwal, K.S. et al. (1992). "Dihydropyrimidine Angiotensin II Receptor Antagonists," J. Med. Chem. 35:4751-4763.							
					<u> </u>			
E	EXAMIN	VER: \	W- Wedolet	DATE CONSIDERED:	1-21-05			
			al if citation considered, whether of not the citation to considered. Include a copy of this form with n		ine through the citation if not in			

Form PTC	-1449		Docket Number 421842000400	Application Number 10/627,372		
INFOR	ITAM	ON DISCLOSURE CITATION	Applicant			
1012		AN APPLICATION	Harrihar A. PERSHADSINGH			
NOV 2 4 201	1 E 1U	se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned		
NUT Z 4 ZW	N &		Mailing Date November 21, 2003			
Vera a	Q.					
AUEHAN	169.	Bernhart, C.A. et al. (1993). "A New S AT <sub>1</sub> Angiotensin II Receptor Antagoni		•		
	170.	Bernobich, E. et al. (2002). "The Role Therapeutic Implications," Drugs 62(9)		ardiac Glucose Homeostasis:		
	171.	Blankley, C.J. et al. (1991). "Synthesis Non-Peptide Angiotensin II Receptor I Chem. 34:3248-3260.	•	•		
	172.	Brasier, A.R. et al. (2000). "Angiotens Dependent Effects on the Nuclear Fact 212:155-169.	• • • • • • • • • • • • • • • • • • •	<u> </u>		
	173.	Brooks, D.A. et al. (2001). "Design and yl)ethoxy]phenoxy}propionic Acids: A 44:2061-2064.		`		
	Bühlmayer, P. et al. (1991). "Nonpeptidic Angiotensin II Antagonists: Synthesis and in of a Series of Novel Naphthalene and Tetrahydronaphthalene Derivatives," J. Med. Che 3114.					
	175.	Carini, D.J. et al. (1991). "Nonpeptide Series of N-(Biphenylylmethyl)Imidaz Chem. 34:2525-2547.	•			
	176.	Cronet, P. et al. (2001). "Structure of the 242; Ligand Selectivity and Agonist A				
	177.	Dahlöf, B. et al. (2002). "Cardiovascul Endpoint Reduction in Hypertension S Lancet 359:995-1003.	•	•		
	178.	Danforth, E. Jr. (2000). "Failure of Ad Nat. Genet. 26:13.	dipocyte Differentiation Causes Type II Diabetes Mellitus?"			
	179.	De, B. et al. (1992). "Discovery of a N Antagonists," J. Med. Chem. 35:3714-	•	n-Peptide Angiotensin II		
	180.	Dhanoa, D.S. et al. (1993). "(Dipropyl) Angiotensin II Receptor Antagonists,"	•	New Generation of Nonpeptide		
	181.	Easthope, S.E. and Jarvis, B. (2002). "General Hypertension," <i>Drugs</i> 62(8):1253-1287	<b>●</b>	e of its Use in Essential		
Ju.	182.	Ellingboe, J.W. et al. (1998). "Metabol Importance of a Second Acidic Group,		onist Tasosartan: The		
EXAMINER: U- celebolités DATE CONSIDERED: 1-21-05						
_		of citation considered, whether or not the citation considered. Include a copy of this form with n		ine through the citation if not in		

Form PTC	)-1449		Docket Number 421842000400	Application Number 10/627,372		
-NEO	RMATI	ON DISCLOSURE CITATION	Applicant			
101 mg	IN	AN APPLICATION '	Harrihar A. PERSHADSINGH			
, , , , , , , , , , , , , , , , , , , ,	E (U	se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned		
NOV 2 4 2000		·	Mailing Date November 21, 2003			
A AN	O					
HADEMAN	183.	Epstein, M. (2002). "Angiotensin II Re	•	•		
le		II Receptor Antagonists Epstein, M. an PA. pp. 257-261.	d Brunner, H.R. eds. Hanley and	d Belfus, Inc.: Philadelphia,		
	184.	Ford, E.S. et al. (2002). "Prevalence of the Third National Health and Nutrition				
	185.	Galvin, P. et al. (1992). "A Simple Met From an Intravenous Glucose Tolerand		The state of the s		
	186.	Groff, J.L. et al. (1993). "Simplified En Clin. Chem. 39(3):400-404.	nzymatic Assay of Angiotensin-	Converting Enzyme in Serum,"		
	187.	Hansson, L. et al. (1999). "Effect of Ar Conventional Therapy on Cardiovascu Prevention Project (CAPPP) Randomis	lar Morbidity and Mortality in H	lypertension: The Captopril		
	188.	Henke, B.R. et al. (1998). "N-(2-Benzo Novel Series of Potent Antihyperglyce 5036.		•		
	189.	Henriksen, E.J. et al. (2001). "Selective Resistance in Obese Zucker Rats," Hyp	•	onism Reduces Insulin		
	190.	Horiuchi, M. et al. (2003). "Fluvastatin Type 1 Receptor Blocker, Valsartan, or				
	191.	Janke, J. et al. (2002). "Mature Adipoc Via Angiotensin Type 1 Receptors," D		ion of Human Preadipocytes		
	192.	Katsuki, A. et al. (2001). "Homeostasis Resistance During Follow-up of Patien				
	193.	Kubo, K. et al. (1993). "Nonpeptide An Activity of Benzimidazoles," J. Med. C	•	sts. Synthesis and Biological		
	194.	Application and Validation of Recently	oolic Syndrome and Development of Diabetes Mellitus: ly Suggested Definitions of the Metabolic Syndrome in a Journal of Epidemiology 156(11):1070-1077.			
	195.	Le Bourdonnec, B. et al. (2000). "Synt 5-diones as AT <sub>1</sub> Receptor Antagonists,		uation of New Pyrazolidine-3,		
	196. Le Bourdonnec, B. et al. (2002). "Comparison of 3D Structures and AT <sub>1</sub> Binding Properties of Pyrazolidine-3,5-diones and Tetrahydropyridazine-3,6-diones with Parent Antihypertensive Drug Irbesartan," J. Med. Chem. 45:4794-4798.					
lle	197.	Lin, H.S. et al. (1992). "Nonpeptide Ar Computational Chemistry of N-[[4-(2h Derivatives and Their In Vitro Activity	I-Tetrazol-5-yl)-1-Cycloalken-1-	-yl]Phenyl]Methyl]Imidazole		
EXAMI	NER:	60- aledets	DATE CONSIDERED:			
		al if citation considered, whether or not the citation to considered. Include a copy of this form with new considered.		ine through the citation if not in		

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449				Docket Number 421842000400	Application Number 10/627,372			
	NEOR	MATIO	ON DISCLOSURE CITATION	Applicant				
/ 0	110		AN APPLICATION	Harrihar A. PERSHADSINGH				
<b>2000</b>	2 4 200	(Us	se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned			
MOV 2 4 2003 😸				Mailing Date November 21, 2003				
To be		G,		· · · · · · · · · · · · · · · · · · ·				
Receptor Blockade in Healthy			macodynamics and Drug Action: Comparative Angiotensin II lunteers: The Importance of Dosing," Clin. Pharmacol. Ther.					
		199.		'Non-Peptide Angiotensin II Receptor Antagonists: Synthesis and vel 4,5-Dihydro-4-oxo-3 <i>H</i> -imidazo(4,5- <i>c</i> )pyridine Derivatives,"				
		200.	Meigs, J.B. et al. (2003). "The Natural History of Progression From Normal Glucose Tolerance to Type 2 Diabetes in the Baltimore Longitudinal Study of Aging," <i>Diabetes</i> 52:1475-1484					
		201. Miyajima, A. et al. (2002). "Angiotensin II Type I Antagonist Prevents Pulmonary Metastasis of Murine Renal Cancer by Inhibiting Tumor Angiogensis," Cancer Res. 62:4176-4179.						
		202. Miyazaki, M. et al. (1999). "Angiotensin II Type I Receptor Antagonist, TCV-116, Prevents Neointima Formation in Injured Arteries in the Dog," Jpn. J. Pharmacol. 79:455-460.						
		," Journal of Clinical						
	204. Norman, M.H. et al. (1995). "4-(Heteroarylthio)-2-biphenylyltetrazoles as Nonpeptide Antagonists," J. Med. Chem. 38:4670-4778.							
		205.	Phillips, M.I. and Kagiyama, S. (2002). "Angiotensin II As A Pro-Inflammatory Mediator," Curr. Opin. Investig. Drugs 3(4):569-577.					
		206.	Sasaki, K. et al. (2002). "Evidence for the Importance of Angiotensin II Type 1 Receptor in Ischemi Induced Angiogenesis," J. Clin. Invest. 109:603-611.					
		207.	Schmidt, B. and Schieffer, B. (2003). "Implications of Active Metabolites," J.	-	_			
	208. Sharma, A.M. et al. (2002). "Angiotensin Blockade Prevents Type 2 Diabetes by Formation Cells," Hypertension 40:609-611.							
209. Shiuchi, T. et al. (2002). "ACE Inhibitor Improves Insulin Bradykinin and NO," Hypertension 40:329-334.					n Diabetic Mouse via			
		210.	Silvestre, J.S. et al. (2002). "Antiangio Induced Angiogenesis in Mice Hindlin		ype 2 Receptor in Ischemia-			
		211.	Smith, K.L. and Tisdale, M.J. (1993). "Mechanism of Muscle Protein Degradation in Cancer Cachexia," British Journal of Cancer 68:314-318.					
		Tamarat, R. et al. (2002). "Angiotensin II Angiogenic Effect in Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways," Lab. Invest. 82(6):747-756.						
W	ນ	213.	Tanaka, Y. et al. (1989). "Antitumor A Carcinoma Compared with Those with	•	<del>-</del>			
E	XAMI	VER: v	D- (eledoles De	DATE CONSIDERED:				
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

Form PTO-1449				Docket Number 421842000400	Application Number 10/627,372					
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				Applicant Harrihar A. PERSHADSINGH						
, MOA	2 4 20	n æru	se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned					
				Mailing Date November 21, 2003						
TE TO	PAOGMARKS									
	Teuscher, A.U. and Weidmann, P.U. (1997). "Requirements for Antihypertensive Therapy in Diabetic Patients: Metabolic Aspects," Journal of Hypertension 15(Supp. 2):S67-S75.									
•		215.	Tham, D.M. et al. (2002). "Angiotensin II Is Associated With Activation of NF-kB-Mediated Genes and Downregulation of PPARs," <i>Physiol. Genomics</i> 11:21-30.							
		216.	Tomiyama, H. et al. (1994). "Kinins Contribute to the Improvement of Insulin Sensitivity During Treatment with Angiotensin Converting Enzyme Inhibitor," <i>Hypertension</i> 23:450-455.							
		217.	Wang, N. et al. (2002). "Constitutive Activation of Peroxisome Proliferator-Activated Receptor-γ Suppresses Pro-Inflammatory Adhesion Molecules in Human Vascular Endothelial Cells," J. Biol. Chem. 277(37):34176-34181.							
		218.	Yusuf, S. et al. (2001). "Ramipril and the Development of Diabetes," JAMA 286:1882-1885.							
((	V	219.	Zimmet, P. et al. (2001). "Global and 3 414:782-787.	). "Global and Societal Implications of the Diabetes Epidemic," Nature						

EXAMINER: 60- selecteles

DATE CONSIDERED:

7-21-05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Sheet 1 f 1

## Form PTO-1449

1

## INFORMATION DISCUSSIFIÉ CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 421842000400	Application Number 10/627,372
Applicant	
Harriha	r A. PERSHADSINGH
Filing Date July 24, 2003	Group Art Unit 1632
Mailing Date May 21, 2004	

•			U.S. PA	ATENT DOCUMENTS				
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate	
Kee	1.	04/25/2002	2002/0048798	Avery et al.				
•								
	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
							<u> </u>	
•	Ref. No.	Title	22222222					

EXAMINER: 40- Wildlett

DATE CONSIDERED:

1-21-05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449				Docket Number 421842000400 Application Number 10/627,372						
DIFO	MATI	ON DISCLO	SURE CITATION	Applicant						
/0"	C 10	AN APPLIC	ATION	Harrihar A. PERSHADSINGH						
AUR O R	2004 S	se several sheets if	necessary)		Filing Date July 24, 2003 Group Art Unit 1632					
AUG 0 6 2004 55				Mailing Date August 3.	Mailing Date August 3, 2004					
FAT & TRADE	MARKOR									
	U.S. PATENT DOCUMENTS									
Examiner	Ref.	Date	Document No.	Name	Class	Subclass	Filing Date If			
Initials	No.			······································			Appropriate			
				·						
	·					,				
	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO			
			·							
	Ref. Title No.									
Ke	1.	Database Medline on STN (Columbus, OH, USA) Document No.: 22006210, Accession No.: 2002271257. Diep, Q. et al. (2002). "Structure, Edothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II- Infused Rats: Role Peroxisome Proliferator-Activated Receptor-Gamma," Circulation 105(9):2296-2302, abstract, 3 pages.								
	2.	Database HCAPLUS on STN (Columbus, OH, USA) Document No.: 133:41183, Accession No.: 2000:195273. Vamecq, J. et al. (2000). "Peroxisome Proliferator-Activated Receptors (PPARs) and Their Implications in Diseases," Current Opinion in Endocrinology & Diabetes 7(1):8-18, abstract, 1 page.								
. 1(4)	3.	International Search Report mailed on June 18, 2004, for PCT patent application no. PCT/US03/24881 filed on August 8, 2003, 5 pages.								
(										
		,					;			
Λ.										
			^							
EXAMIN	IER: (	e W	holdert	DATE CONSIL	DERED: \ -	2015				
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.										